Combined drug and radiation therapy for advanced pancreatic cancer

This trial is testing a combination approach for pancreatic cancer that has spread within the abdomen but not to distant parts of the body. The treatment combines two chemotherapy drugs (nab-paclitaxel and gemcitabine), an immunotherapy medication called serplulimab, and a special type of radiation therapy called stereotactic body radiation therapy (SBRT). The goal is to shrink the tumor and potentially allow patients to have surgery later.

Locally advanced pancreatic cancer is very difficult to treat because the tumor is often too large or intertwined with important blood vessels to remove safely with surgery right away. This trial exists to see if using multiple types of treatment together—drugs to kill cancer cells plus focused radiation to attack the tumor directly—might work better than current approaches.